Treating Individuals 4 - Can meta-analysis help target interventions at individuals most likely to benefit?

被引:140
作者
Thompson, SG [1 ]
Higgins, JPT [1 ]
机构
[1] Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England
基金
英国医学研究理事会;
关键词
D O I
10.1016/S0140-6736(05)17790-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Meta-analyses of randomised trials aim to summarise the effects of interventions across many patients, and can seem remote from the clinical issue of how individual patients should be treated and which patient groups will benefit the most from treatment. One method that attempts to address this point entails relating the overall effect in every trial to summaries of patient characteristics. This is called meta-regression. The interpretation of such analyses is not straightforward, however, because of a combination of confounding and other biases. Much more useful is to compare the outcomes for patient subgroups within trials and combine these results across trials. Unfortunately this method is rarely possible using published information, so analyses of individual patient data from trials are necessary. Also, although meta-analyses generally summarise an intervention's effect as a relative risk reduction, the groups of patients with the greatest absolute risk reduction have the most to gain.
引用
收藏
页码:341 / 346
页数:6
相关论文
共 51 条
[1]  
Altman DG, 1990, PRACTICAL STAT MED R
[2]  
[Anonymous], 2001, SYSTEMATIC REV HLTH, DOI DOI 10.1002/9780470693926
[3]  
[Anonymous], 2000, GUID US GLYC 2B 3A I
[4]   INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].
APPLEBY, P ;
BAIGENT, C ;
COLLINS, R ;
FLATHER, M ;
PARISH, S ;
PETO, R ;
BELL, P ;
HALLS, H ;
MEAD, G ;
DIAZ, R ;
PAOLASSO, E ;
PAVIOTTI, C ;
ROMERO, G ;
CAMPBELL, T ;
OROURKE, MF ;
THOMPSON, P ;
LESAFFRE, E ;
VANDEWERF, F ;
VERSTRAETE, M ;
ARMSTRONG, PW ;
CAIRNS, JA ;
MORAN, C ;
TURPIE, AG ;
YUSUF, S ;
GRANDE, P ;
HEIKKILA, J ;
KALA, R ;
BASSAND, JP ;
BOISSEL, JP ;
BROCHIER, M ;
LEIZOROVICZ, A ;
BRUGGEMANN, T ;
KARSCH, KR ;
KASPER, W ;
LAMMERTS, D ;
NEUHAUS, KL ;
MEYER, J ;
SCHRODER, R ;
VONESSEN, R ;
SARAN, RK ;
ARDISSINO, D ;
BONADUCE, D ;
BRUNELLI, C ;
CERNIGLIARO, C ;
FORESTI, A ;
FRANZOSI, MG ;
GUIDUCCI, D ;
MAGGIONI, A ;
MAGNANI, B ;
MATTIOLI, G .
LANCET, 1994, 343 (8893) :311-322
[5]   Subgroup analysis and other (mis)uses of baseline data in clinical trials [J].
Assmann, SF ;
Pocock, SJ ;
Enos, LE ;
Kasten, LE .
LANCET, 2000, 355 (9209) :1064-1069
[6]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[7]   GENERALIZING THE RESULTS OF RANDOMIZED CLINICAL-TRIALS [J].
BAILEY, KR .
CONTROLLED CLINICAL TRIALS, 1994, 15 (01) :15-23
[8]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1498
[9]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1488
[10]   A RANDOM-EFFECTS REGRESSION-MODEL FOR METAANALYSIS [J].
BERKEY, CS ;
HOAGLIN, DC ;
MOSTELLER, F ;
COLDITZ, GA .
STATISTICS IN MEDICINE, 1995, 14 (04) :395-411